GENERAL INFORMATION
Established:  1994
Type:  Graduated from Technological Incubator
Ownership:  Private

Core business

Development and commercialization of recombinant therapeutic
proteins.

Employees:  100
Main Markets:  Pharmaceutical and nutraceutical

Overview

PROTALIX BIOTHERAPEUTICS LTD. (formerly METABOGAL Ltd.) is a
publicly traded, clinical stage biopharmaceutical company (AMEX:
PLX).

The company is focused on the development and commercialization
of recombinant therapeutic proteins based on its proprietary
protein expression system, ProCellEx, which is superior in terms
of efficacy, safety and economics. PROTALIX' lead product
development candidate, prGCD for the treatment of Gaucher
disease, is in phase III clinical trial. Additionally, PROTALIX
has an innovative product pipeline based on ProCellEx protein
expression system, including various proprietary therapeutic
protein candidates which will enable the company to file
additional investigational new drug applications.

PROTALIX has a wide, established Patent estate, covering all
aspects of the technology, products and platform improvements
(method, device, composition of matter) and several strategic
collaborations in place. PROTALIX' business strategy is to use
its ProCellEx platform to develop PROTALIX owned proprietary
therapeutic proteins as well as to form strategic partnerships
with biopharmaceutical companies for large scale production of
complex recombinant therapeutic proteins.

PROTALIX aims to become a leading fully integrated
biopharmaceutical company focused on the development and
commercialization of proprietary recombinant therapeutic
proteins. PROTALIX' mission is to utilize its exceptional protein
production technology in order to commercialize a pipe-line of
protein based drugs, both novel, ethical proteins and Biogeneric
therapeutics.